- Home
- NCI vs HOTH Comparison
NCI vs HOTH Comparison
Compare NCI & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- HOTH
- Stock Information
- Founded
- NCI 1992
- HOTH 2017
- Country
- NCI Hong Kong
- HOTH United States
- Employees
- NCI N/A
- HOTH N/A
- Industry
- NCI
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- NCI
- HOTH Health Care
- Exchange
- NCI NYSE
- HOTH Nasdaq
- Market Cap
- NCI 7.4M
- HOTH 8.3M
- IPO Year
- NCI 2024
- HOTH 2019
- Fundamental
- Price
- NCI $2.47
- HOTH $1.14
- Analyst Decision
- NCI
- HOTH Strong Buy
- Analyst Count
- NCI 0
- HOTH 3
- Target Price
- NCI N/A
- HOTH $4.00
- AVG Volume (30 Days)
- NCI 157.8K
- HOTH 3.0M
- Earning Date
- NCI 07-07-2025
- HOTH 05-12-2025
- Dividend Yield
- NCI N/A
- HOTH N/A
- EPS Growth
- NCI 67.70
- HOTH N/A
- EPS
- NCI 0.26
- HOTH N/A
- Revenue
- NCI $30,340,230.00
- HOTH N/A
- Revenue This Year
- NCI N/A
- HOTH N/A
- Revenue Next Year
- NCI N/A
- HOTH N/A
- P/E Ratio
- NCI $8.88
- HOTH N/A
- Revenue Growth
- NCI 35.28
- HOTH N/A
- 52 Week Low
- NCI $1.40
- HOTH $0.58
- 52 Week High
- NCI $9.00
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- HOTH 51.11
- Support Level
- NCI N/A
- HOTH $1.15
- Resistance Level
- NCI N/A
- HOTH $1.34
- Average True Range (ATR)
- NCI 0.00
- HOTH 0.13
- MACD
- NCI 0.00
- HOTH -0.02
- Stochastic Oscillator
- NCI 0.00
- HOTH 19.44
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company that is a one-stop apparel solution services provider. The company offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European and North American markets.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.